Literature DB >> 33929718

FABP5 Deficiency Impairs Mitochondrial Function and Aggravates Pathological Cardiac Remodeling and Dysfunction.

Shanquan Gao1, Guoqi Li1, Yihui Shao1, Zhipeng Wei1, Shan Huang1, Feiran Qi1, Yao Jiao1, Yulin Li1, Congcong Zhang2, Jie Du3.   

Abstract

Fatty acid-binding protein 5 (FABP5) is an important member of the FABP family and plays a vital role in the metabolism of fatty acids. However, few studies have examined the role of FABP5 in pathological cardiac remodeling and heart failure. The aim of this study was to explore the role of FABP5 in transverse aortic constriction (TAC)-induced pathological cardiac remodeling and dysfunction in mice. Quantitative RT-PCR (qRT-PCR) and western blotting (WB) analysis showed that the levels of FABP5 mRNA and protein, respectively, were upregulated in hearts of the TAC model. Ten weeks after TAC in FABP5 knockout and wild type control mice, echocardiography, histopathology, qRT-PCR, and WB demonstrated that FABP5 deficiency aggravated cardiac injury (both cardiac hypertrophy and fibrosis) and dysfunction. In addition, transmission electron microscopy, ATP detection, and WB revealed that TAC caused severe impairment to mitochondria in the hearts of FABP5-deficient mice compared with that in control mice. When FABP5 was downregulated by siRNA in primary mouse cardiac fibroblasts, FABP5 silencing increased oxidative stress, reduced mitochondrial respiration, and increased the expression of myofibroblast activation marker genes in response to treatment with transforming growth factor-β. Our findings demonstrate that FABP5 deficiency aggravates cardiac pathological remodeling and dysfunction by damaging cardiac mitochondrial function.

Entities:  

Keywords:  Cardiac dysfunction; Cardiac fibroblasts; FABP5; Pathological cardiac remodeling

Mesh:

Substances:

Year:  2021        PMID: 33929718     DOI: 10.1007/s12012-021-09653-2

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  34 in total

Review 1.  Cardiac metabolism in heart failure: implications beyond ATP production.

Authors:  Torsten Doenst; Tien Dung Nguyen; E Dale Abel
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

Review 2.  Metabolic remodelling in heart failure.

Authors:  Edoardo Bertero; Christoph Maack
Journal:  Nat Rev Cardiol       Date:  2018-08       Impact factor: 32.419

Review 3.  Pathophysiology of Heart Failure.

Authors:  Edit Tanai; Stefan Frantz
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

Review 4.  Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association.

Authors:  Heinrich Taegtmeyer; Martin E Young; Gary D Lopaschuk; E Dale Abel; Henri Brunengraber; Victor Darley-Usmar; Christine Des Rosiers; Robert Gerszten; Jan F Glatz; Julian L Griffin; Robert J Gropler; Hermann-Georg Holzhuetter; Jorge R Kizer; E Douglas Lewandowski; Craig R Malloy; Stefan Neubauer; Linda R Peterson; Michael A Portman; Fabio A Recchia; Jennifer E Van Eyk; Thomas J Wang
Journal:  Circ Res       Date:  2016-03-24       Impact factor: 17.367

5.  Fatty acid binding protein (Fabp) 5 interacts with the calnexin cytoplasmic domain at the endoplasmic reticulum.

Authors:  Joanna Jung; Jessica Wang; Jody Groenendyk; Dukgyu Lee; Marek Michalak; Luis B Agellon
Journal:  Biochem Biophys Res Commun       Date:  2017-09-11       Impact factor: 3.575

Review 6.  Epidemiology of heart failure with preserved ejection fraction.

Authors:  Shannon M Dunlay; Véronique L Roger; Margaret M Redfield
Journal:  Nat Rev Cardiol       Date:  2017-05-11       Impact factor: 32.419

Review 7.  Myocardial fatty acid metabolism in health and disease.

Authors:  Gary D Lopaschuk; John R Ussher; Clifford D L Folmes; Jagdip S Jaswal; William C Stanley
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

Review 8.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

9.  Molecular pathways underlying cardiac remodeling during pathophysiological stimulation.

Authors:  Izhak Kehat; Jeffery D Molkentin
Journal:  Circulation       Date:  2010-12-21       Impact factor: 29.690

Review 10.  Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review.

Authors:  Vincenzo Mollace; Giuseppe M C Rosano; Stefan D Anker; Andrew J S Coats; Petar Seferovic; Rocco Mollace; Annamaria Tavernese; Micaela Gliozzi; Vincenzo Musolino; Cristina Carresi; Jessica Maiuolo; Roberta Macrì; Francesca Bosco; Marcello Chiocchi; Francesco Romeo; Marco Metra; Maurizio Volterrani
Journal:  Nutrients       Date:  2021-01-17       Impact factor: 5.717

View more
  4 in total

1.  Transcriptomic and Lipidomic Mapping of Macrophages in the Hub of Chronic Beta-Adrenergic-Stimulation Unravels Hypertrophy-, Proliferation-, and Lipid Metabolism-Related Genes as Novel Potential Markers of Early Hypertrophy or Heart Failure.

Authors:  Sophie Nadaud; Mathilde Flamant; Wilfried Le Goff; Elise Balse; Catherine Pavoine
Journal:  Biomedicines       Date:  2022-01-20

Review 2.  Alternative autophagy: mechanisms and roles in different diseases.

Authors:  Hong Feng; Nian Wang; Nan Zhang; Hai-Han Liao
Journal:  Cell Commun Signal       Date:  2022-03-31       Impact factor: 5.712

3.  Fatty acid-binding protein 5 aggravates pulmonary artery fibrosis in pulmonary hypertension secondary to left heart disease via activating wnt/β-catenin pathway.

Authors:  Qian Lei; Zhimin Yu; Hang Li; Jun Cheng; Yanggan Wang
Journal:  J Adv Res       Date:  2021-11-26       Impact factor: 12.822

Review 4.  Mitochondria in Pathological Cardiac Hypertrophy Research and Therapy.

Authors:  Dan Yang; Han-Qing Liu; Fang-Yuan Liu; Zhen Guo; Peng An; Ming-Yu Wang; Zheng Yang; Di Fan; Qi-Zhu Tang
Journal:  Front Cardiovasc Med       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.